Droxidopa
Northera (droxidopa) is a small molecule pharmaceutical. Droxidopa was first approved as Northera on 2014-02-18. It is used to treat orthostatic hypotension in the USA. It is known to target muscarinic acetylcholine receptor M1.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Northera (generic drugs available since 2021-02-18)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Droxidopa
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NORTHERA | Lundbeck | N-203202 RX | 2014-02-18 | 3 products, RLD, RS |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
128 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 11 | — | — | 1 | 1 | 13 | ||
| Pain | D010146 | EFO_0003843 | R52 | 2 | 2 | — | 1 | — | 5 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 1 | — | — | 2 | 2 | 5 |
| Postoperative pain | D010149 | G89.18 | — | 2 | 1 | 1 | — | 3 | |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | — | 1 | 1 | — | 2 |
| Head and neck neoplasms | D006258 | — | — | — | 1 | — | 1 | ||
| Lung neoplasms | D008175 | C34.90 | — | — | — | 1 | — | 1 | |
| Pregnancy rate | D018873 | — | — | — | 1 | — | 1 | ||
| Esophageal diseases | D004935 | EFO_0009544 | K22.9 | — | — | — | 1 | — | 1 |
| Replacement arthroplasty knee | D019645 | — | — | — | 1 | — | 1 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Marijuana abuse | D002189 | EFO_0007191 | F12 | 3 | 6 | 2 | — | 3 | 11 |
| Vomiting | D014839 | HP_0002013 | R11.1 | 2 | 3 | 3 | — | — | 7 |
| Chronic pain | D059350 | HP_0012532 | 1 | 4 | 1 | — | — | 5 | |
| Neoplasms | D009369 | C80 | 1 | 2 | 1 | — | — | 3 | |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | 1 | 2 | — | — | 3 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | 1 | 1 | — | 1 | 2 | |
| Trichotillomania | D014256 | HP_0012167 | F63.3 | — | 2 | 1 | — | — | 2 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | 1 | 1 | — | 1 | 2 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | 1 | — | — | 2 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | 1 | 1 | — | — | 1 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cannabis | D002188 | 6 | 1 | — | — | 1 | 8 | ||
| Hiv infections | D015658 | EFO_0000764 | B20 | 4 | 2 | — | — | — | 5 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 3 | 1 | — | — | 1 | 4 |
| Nausea | D009325 | HP_0002018 | R11.0 | 2 | 2 | — | — | — | 3 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 2 | — | — | — | 2 |
| Dementia | D003704 | F03 | — | 2 | — | — | — | 2 | |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | 1 | — | — | — | 2 |
| Tourette syndrome | D005879 | EFO_0004895 | F95.2 | — | 2 | — | — | — | 2 |
| Abdominal pain | D015746 | R10.9 | — | 2 | — | — | — | 2 | |
| Renal circulation | D012079 | — | 1 | — | — | 1 | 2 |
Show 26 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psychotic disorders | D011618 | F20.81 | 4 | — | — | — | — | 4 | |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 2 | — | — | — | — | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | — | — | — | — | 2 |
| Psychomotor disorders | D011596 | 1 | — | — | — | 1 | 2 | ||
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 2 | — | — | — | — | 2 |
| Dual (psychiatry) diagnosis | D017831 | 2 | — | — | — | — | 2 | ||
| Adolescent behavior | D000294 | 1 | — | — | — | — | 1 | ||
| Biological availability | D001682 | 1 | — | — | — | — | 1 | ||
| Problem behavior | D000066553 | 1 | — | — | — | — | 1 | ||
| Therapeutic equivalency | D013810 | 1 | — | — | — | — | 1 |
Show 7 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adolescent development | D041923 | — | — | — | — | 1 | 1 | ||
| Appetite regulation | D001069 | — | — | — | — | 1 | 1 | ||
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | — | — | — | — | 1 | 1 |
| Muscle cramp | D009120 | HP_0003394 | — | — | — | — | 1 | 1 | |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
| Overweight | D050177 | E66.3 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DROXIDOPA |
| INN | droxidopa |
| Description | Droxidopa is a serine derivative that is L-serine substituted at the beta-position by a 3,4-dihydroxyphenyl group. A prodrug for noradrenalone, it is used for treatment of neurogenic orthostatic hypotension It has a role as a prodrug, a vasoconstrictor agent and an antihypertensive agent. It is a L-tyrosine derivative and a member of catechols. |
| Classification | Small molecule |
| Drug class | dopamine receptor agonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 23651-95-8 |
| RxCUI | 1489913 |
| ChEMBL ID | CHEMBL2103827 |
| ChEBI ID | 31524 |
| PubChem CID | 92974 |
| DrugBank | DB06262 |
| UNII ID | J7A92W69L7 (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 574 documents
View more details
Safety
Black-box Warning
Black-box warning for: Droxidopa, Northera
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,224 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more